BR112021021923A2 - Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite - Google Patents

Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite

Info

Publication number
BR112021021923A2
BR112021021923A2 BR112021021923A BR112021021923A BR112021021923A2 BR 112021021923 A2 BR112021021923 A2 BR 112021021923A2 BR 112021021923 A BR112021021923 A BR 112021021923A BR 112021021923 A BR112021021923 A BR 112021021923A BR 112021021923 A2 BR112021021923 A2 BR 112021021923A2
Authority
BR
Brazil
Prior art keywords
antibodies
treatment
insulitis
therapies
kits
Prior art date
Application number
BR112021021923A
Other languages
English (en)
Inventor
Allison Goldfine
James Rush
Pascal Espie
Rainer Mussmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112021021923A2 publication Critical patent/BR112021021923A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpos anti-cd40 para uso no tratamento de dm1 e insulite. a presente invenção refere-se a métodos, regimes de tratamento, usos, kits e terapias para o tratamento de dm1 utilizando-se anticorpos anti-cd40.
BR112021021923A 2019-05-08 2020-05-06 Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite BR112021021923A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962844960P 2019-05-08 2019-05-08
PCT/IB2020/054271 WO2020225736A1 (en) 2019-05-08 2020-05-06 Anti-cd40 antibodies for use in treatment of t1dm and insulitis

Publications (1)

Publication Number Publication Date
BR112021021923A2 true BR112021021923A2 (pt) 2022-02-22

Family

ID=70680549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021923A BR112021021923A2 (pt) 2019-05-08 2020-05-06 Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite

Country Status (13)

Country Link
US (1) US20220195061A1 (pt)
EP (1) EP3966240A1 (pt)
JP (2) JP2021518854A (pt)
KR (1) KR20220007086A (pt)
CN (1) CN113784985A (pt)
AU (1) AU2020267953A1 (pt)
BR (1) BR112021021923A2 (pt)
CA (1) CA3137682A1 (pt)
CL (1) CL2021002889A1 (pt)
IL (1) IL287464A (pt)
MX (1) MX2021013631A (pt)
TW (1) TW202108617A (pt)
WO (1) WO2020225736A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
TW200540186A (en) 2003-12-25 2005-12-16 Kirin Brewery Mutants of anti-CD40 antibody
DK1889065T3 (da) * 2005-05-18 2013-09-02 Xoma Technology Ltd Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
HUE038788T2 (hu) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN116063481A (zh) * 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
MX2020010722A (es) * 2018-04-13 2020-11-06 Novartis Ag Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.

Also Published As

Publication number Publication date
JP2021518854A (ja) 2021-08-05
EP3966240A1 (en) 2022-03-16
CL2021002889A1 (es) 2022-08-12
JP2022116272A (ja) 2022-08-09
WO2020225736A1 (en) 2020-11-12
KR20220007086A (ko) 2022-01-18
TW202108617A (zh) 2021-03-01
US20220195061A1 (en) 2022-06-23
AU2020267953A1 (en) 2021-11-18
CN113784985A (zh) 2021-12-10
MX2021013631A (es) 2022-04-12
IL287464A (en) 2021-12-01
CA3137682A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
BR112017023576A2 (pt) Método para tratar uma disfunção proliferativa de células b
CO2018000867A2 (es) Moléculas de unión a pd-1 y métodos de uso de las mismas
CO2017012553A2 (es) Moléculas de unión a lag-3
CL2017000335A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
EA201890390A8 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
MX2020013468A (es) Anticuerpos il-11ra.
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2019086497A3 (en) Combination therapy with targeted ox40 agonists
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
EA201892525A1 (ru) Конструкции днк-антител для применения против pseudomonas aeruginosa
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112019008241A2 (pt) tratamento do prurigo nodular
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa